(Q36336035)

13 August 2017

The pharmacokinetics of oxypurinol in people with gout (English)

1 reference

13 August 2017

1 reference

Carl M Kirkpatrick

4

0 references

Andrew J. McLachlan

object named as

Andrew J McLachlan

2

0 references

Richard O. Day

object named as

Richard O Day

7

0 references

author name string

Sophie L Stocker

1

1 reference

13 August 2017

Radojka M Savic

3

1 reference

13 August 2017

Garry G Graham

5

1 reference

13 August 2017

Kenneth M Williams

6

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 September 2012

1 reference

British Journal of Clinical Pharmacology

13 August 2017

1 reference

13 August 2017

74

1 reference

13 August 2017

3

1 reference

13 August 2017

477-489

1 reference

The SLC2A9 nonsynonymous Arg265His variant and gout: evidence for a population-specific effect on severity

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477349

Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477349

Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477349

Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477349

Adherence with urate-lowering therapies for the treatment of gout

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477349

Comparison of drug adherence rates among patients with seven different medical conditions.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477349

SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477349

Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477349

Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477349

Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477349

Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477349

Population pharmacokinetics of allopurinol in full-term neonates with perinatal asphyxia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477349

Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477349

Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477349

Molecular identification of a renal urate anion exchanger that regulates blood urate levels

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477349

Effect of furosemide on renal excretion of oxypurinol and purine bases

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477349

Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477349

Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477349

Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477349

Geriatric Pharmacology: Basic and Clinical Considerations*

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477349

Prediction of creatinine clearance from serum creatinine

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477349

Type 1 sodium-dependent phosphate transporter (SLC17A1 Protein) is a Cl(-)-dependent urate exporter

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477349

Lean body mass normalizes the effect of obesity on renal function.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477349

Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477349

Physiologic and clincical observations on furosemide and ethacrynic acid

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477349

A survey of current prescribing practices of anti-inflammatory and urate-lowering drugs in gouty arthritis in New South Wales and Queensland.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477349

Digoxin in the elderly: Pharmacokinetic consequences of old age

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477349

Bioequivalence of allopurinol preparations: to be assessed by the parent drug or the active metabolite?

29 June 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2012.04207.X

Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2012.04207.X

Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2012.04207.X

Quantification of lean bodyweight.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2012.04207.X

Model appropriateness and population pharmacokinetic modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2012.04207.X

Interactions of human organic anion transporters with diuretics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2012.04207.X

Sodium-dependent phosphate cotransporter type 1 sequence polymorphisms in male patients with gout.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2012.04207.X

Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2012.04207.X

Relationships between beliefs about medications and nonadherence to prescribed chronic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2012.04207.X

Renal clearance of oxipurinol, the chief metabolite of allopurinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2012.04207.X

A strong role for the ABCG2 gene in susceptibility to gout in New Zealand Pacific Island and Caucasian, but not Māori, case and control sample sets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2012.04207.X

Dosage prescribing and plasma oxipurinol levels in patients receiving allopurinol therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2012.04207.X

Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness

21 January 2018

1 reference

12 December 2020

[The bioequivalence of a new allopurinol tablet formulation in comparison to a reference formulation]

1 reference

12 December 2020

Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level

1 reference

12 December 2020

Plasma oxipurinol concentrations during allopurinol therapy

1 reference

12 December 2020

Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout

1 reference

12 December 2020

Disposition and uric acid lowering effect of oxipurinol: comparison of different oxipurinol formulations and allopurinol in healthy individuals

1 reference

12 December 2020

Clinical practice. Gout

1 reference

12 December 2020

[A study of serum oxipurinol concentration and renal function in patients administered allopurinol]

1 reference

12 December 2020

10.1111/J.1365-2125.2012.04207.X

Identifiers

DOI

1 reference

13 August 2017

1 reference

13 August 2017

PubMed publication ID

22300439

1 reference